Introduction
In 1968, the Japanese Society of Chemotherapy (JSC) established an agar dilution method for MIC determinations of aerobic bacteria [1] . In 1979, the JSC established an agar dilution method for MIC determinations of anaerobic bacteria. Furthermore, a revision of the agar dilution standard was made in 1980, and this served as the standard method for MIC determinations for an extensive period of time in Japan. In 1990, the committee established a standard microbroth dilution method for MIC determinations. This method was modified in 1992 for fastidious aerobic and anaerobic bacteria [2] .
In the development of standards for antimicrobial susceptibility testing, there has been a movement to incorporate pharmacologic as well as clinical considerations with respect to in vitro antimicrobial susceptibility interpretations. This trend reflects the need to respond to the emergence and spread of resistant microorganisms as well as a greater understanding of pharmacokinetics and pharmacodynamics and how it relates to improved patient outcome. The Clinical Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility (EUCAST) are among the professional organizations that proactively revise antimicrobial susceptibility testing on a regular basis. JSC has also been revising its standards. In 2007, the agar dilution method was revised. After the exclusion of selected organisms from the CLSI agar dilution standard, this method was adopted by the JSC [3] .
With respect to revising the standard method for microbroth dilution antimicrobial susceptibility testing, a committee chaired by Keizo Yamaguchi was formed in January 2008. The subcommittee's first task was to critically examine the methods for the antimicrobial susceptibility testing of Haemophilus influenzae. Although JSC and CLSI microbroth dilution methods both use a MuellerHinton base, the supplements differ. This difference had raised concerns among some Japanese clinical microbiology professionals that there were many issues with the CLSI method with respect to reported difficulties in measuring endpoints and the poor growth of some strains.
Our first action was to send questionnaires to the members of the JSC and the Japanese Society for Clinical Microbiology to better understand the technical problems experienced in clinical microbiology laboratories regarding microbroth dilution testing of H. influenzae. From the responses to the questionnaire, it was clear that a major problem in routine testing was the poor growth of H. influenzae isolates when the CLSI standard using Haemophilus Test Medium Broth (HTM) was employed. Based on this overwhelming response, we set out to reexamine the performance of H. influenzae microbroth dilution testing methods at participating clinical microbiology laboratories located in different geographical areas of Japan.
Materials and methods

Phase I studies
During this phase, we undertook a bacteriological investigation of differences between the CLSI HTM and the JSC media for microbroth dilution susceptibility testing of H. influenzae. Factors studied included lot differences as well as other factors related to test performance.
Methodology
Dried microbroth dilution plates (Eiken Chemical) for testing H. influenzae were prepared using three lots of cation-adjusted Mueller-Hinton broth (CAMHB) to which hematin, NAD and yeast extract were added according to the CLSI, whereas the supplements in the JSC method were lysed horse blood, yeast extract and NAD. The respective lots were labeled A, B and C and used at seven cooperating laboratories to test two QC organisms: H. influenzae ATCC 49247, which is b-lactamase negative and ampicillin resistant (BLNAR), and H. influenzae ATCC 49766. Each lot of media was tested 30 times by both the JSC and CLSI methods at each facility, and the geometric mean was determined for each respective lot.
Antimicrobial agents tested
The following 8 antimicrobial agents were tested using twofold dilutions by both methods on all lots: ampicillin (ABPC 0.06-128 lg/ml); amoxicillin/clavulanic acid (ACV 0.06/0.03-64/32 lg/ml; trimethoprim-sulfamethoxazole (T/S 0.004/0.07-8/152 lg/ml), azithromycin (AZM 0.06-64 lg/ml), cefdinir (CFDN 0.03-64 lg/ml) and ciprofloxacin (CPFX 0.001-2 lg/ml).
Antimicrobial susceptibility test media
The supplements added to cation-adjusted Mueller-Hinton broth in the JSC and CLSA methods are shown in Table 1 .
Adjustment of inoculum density
A bacterial suspension matching the turbidity of a 0.5 McFarland standard was prepared in MHB or physiological saline using isolates grown on chocolate agar plates under 5% CO 2 at 35 ± 2°C for 20-24 h. From the adjusted suspension, 50 ll was added to 13 ml of the JSC-and CLSI-specified broths. After thoroughly mixing to ensure an even suspension, 100 ll were dispensed into the corresponding microdilution wells within 15 min. Trays were incubated in ambient air for 20-24 h at 35 ± 2°C prior to endpoint readings.
Assessment of lot-to-lot variation in test performance
The antimicrobial agents tested to assess lot variation were based on quality control standards established by the CLSI. Meropenem and cefdinir were excluded from the antimicrobial panel for testing H. influenzae ATCC 49247. For meropenem and cefdinir testing, H. influenzae ATCC 49766 was utilized.
Lot performance was considered satisfactory if no more than 2 out of 30 consecutive results for each drug-reference strain combination were outside the acceptable limits established by the CLSI. If this frequency was exceeded, the lot was excluded from the study. Furthermore, data from facilities where quality-control MICs exceeded the acceptable range of results by more than 5% were excluded from the comparison of CLSI and JSC methodologies, although data generated for lot-to-lot variation were included. 
Statistical analysis
Analysis of factors affecting MIC determinations
The methodology employed was identical to that of phase I. Eiken Chemical cation-adjusted Mueller-Hinton dried microbroth dilution plates were supplemented with additives according to the JSC and CLSI. One lot was chosen for testing among lots that was within acceptable CLSI ranges when tested by reference quality-control strains.
For interlaboratory precision studies, the following isolates were used: (a) 40 reference isolates (20 which grew well on media and 20 which grew poorly on media; isolates included BLNAR, b-lactamase non-producing, ampicillinsusceptible (BLNAS), and b-lactamase-producing, ampicillin-resistant (BLPAR) organisms); (b) 30 non-duplicate isolates recovered at participating sites during the period October to December 2008.
During phase II, the geometric mean MIC value for each antimicrobial agent tested was determined for each participating site. The geometric mean MIC values generated by the CLSI and JSC methods during interlaboratory studies using 40 reference organisms as well as consecutively recovered isolates at each participating site were compared with respect to statistically significant differences. Similar to phase I of the project, if the qualitycontrol MIC for a particular drug/reference strain exceeded the acceptable range of results by more than 5%, the geometric mean MIC value for that particular drug was excluded from the data.
Comparison of growth on the CLSI and JSC test method media
Two approaches were used in growth comparisons. In the interlaboratory comparative study using 40 reference organisms, the growth comparison was based on the visual assessment of a designated investigator at each facility. In the second approach, the 40 reference organisms were characterized as BLNAR, low BLNAR, BLNAS and BLPAR based on the presence or absence of TEM type b-lactamase and mutations within the ftsI gene. After 24 and 48 h of incubation, the turbidity (600 nm OD) was compared at Mitsubishi Chemical Medience, Chemotherapy Division.
Primers for detection of H. influenzae resistance genes (Wakunaga Pharmaceutical Co, Osaka) were used according to the manufacturer's protocol. On the basis of the PCR results, isolates demonstrating only a Lys-526 substitution in the ftsI gene were identified as low-BLNAR consistent with low-level b-lactam resistance. Isolates lacking all resistance genes were classified as BLNAS. 
Statistics
Results
Phase I studies
Using the H. influenzae ATCC 49247 and ATCC 49266 strains, the performances of lots A, B, and C were evaluated to determine whether MICs generated for the drugs tested were within acceptable quality-control MIC ranges for the reference strains. While the MICs for azithromycin were somewhat lower when using the CLSI method rather than the JSC method, the MICs generated by both methods were comparable in all lots tested (Table 2) .
Phase II studies
Factors affected MIC values
Interlaboratory MICs generated using 40 reference strains Table 3 shows interlaboratory geometric mean MICs generated for each participating facility using both the JSC and the CLSI methods for all lots tested. With respect to b-lactam antimicrobial agents, the geometric mean MICs based on the JSC method were significantly higher than the CLSI method (p \ 0.05). This difference was most pronounced with ABPC, where the ratio between the JSC and CLSI method was 1.86 (p \ 0.0064). The antimicrobial agent that gave the lowest JSC/CLSI method ratio difference was CTRX, with 1.22 (p = 0.0123).
A similar trend was even observed for AZM, with the MICs generated by the JSC method being higher than those obtained with the CLSI method, as shown by a JSC/CLSI method ratio of 1.60 (p = 0.0003). For CPFX, the JSC/CLSI ratio was lower at 1.21, although there was still a significant difference (p = 0.0034). The one exception was seen with T/S, where the CLSI geometric mean MIC was higher (JSC/CLSI ratio of 0.64, p = 0.0004).
MICs generated at each site for consecutive clinical isolates The interlaboratory results in Table 4 show that, although the differences are not as striking as those observed with the 40 reference strains, higher MICs were obtained for b-lactams with the JSC method. Statistically significant differences were observed for ABPC and CFDN (p = 0.0124 and 0.0420, respectively). The MIC results were also similar for AZM, as the JSC geometric mean MICs were significantly higher than MICs generated using the CLSI method (p = 0.0025). For T/S, the mean MICs were again higher with the CLSI method (p = 0.0030). Although a statistically significant difference was not seen, the CPFX MICs generated by the JSC method were somewhat higher.
Comparison of growth on media used in the JSC and CLSI methods Assessment of growth reported from participating sites In Table 5 , the results of interlaboratory growth assessments for JSC and CLSI media using 40 reference strains are displayed for the 6 participating sites. When growth was classified as either good growth, poor growth observed in some wells, or poor growth, a geometric mean of 35.83 of the isolates were reported to grow well on JSC media Geometric mean MICs (lg/ml) compared to 31.83 for the CLSI media. Poor growth in some wells was observed in 3.17 isolates with JSC media compared to 7.00 isolates on the CLSI media. Poor overall growth was seen in 2.67 isolates using the JSC media compared to 2.83 on the CLSI media. While no statistical difference was observed with visual readings, the overall assessment was that there was superior growth using the JSC method.
Comparative assessment of growth using the JSC and CLSI methods by OD readings The results of an interlaboratory growth assessment based on OD readings at 24 and 48 h of incubation for the JSC and CLSI methods using 40 reference strains are displayed for the 6 participating sites in Table 6 . The data were further analyzed by dividing the 40 H. influenzae isolates up based on the presence of ABPC resistance genes (BLNAR, low-BLNAR, BLNAS and BLPAR). After 24 h of incubation, a higher OD was observed for the JSC method (p \ 0.0001). The difference was most pronounced at 48 h of incubation (p \ 0.0001). For BLNAS, there was no significant growth difference at 24 h, although superior growth at 48 h was observed with the JSC method (Table 7a-d) .
Discussion
In early 2008, members of the Japanese Chemotherapy Society working in clinical laboratories or engaged in research activities as well as members of the Japanese Society for Clinical Microbiology were sent questionnaires on reported issues with the microbroth dilution testing of H. influenzae. Among the 1,348 surveys sent out, there were responses from 464 members; 76% of those members were employed in clinical laboratories, and 2.6% were employed in research activities. Of those responding, 80% reported that microbroth dilution testing was used at their institutions and that 76% of those performing microbroth dilution testing followed the CLSI procedure. The most frequent problem reported when testing the antimicrobial sensitivity of H. influenzae using the CLSI method was the difficulty involved in interpreting endpoints. It was previously believed that the addition of animal blood products to the medium to satisfy the complex growth requirements of H. influenzae complicated the interpretation of antimicrobial susceptibility test results [4] . Complex additives can also contribute to lot-to-lot variability in media performance. In order to improve the reliability of H. influenzae antimicrobial susceptibility testing, Jorgensen et al. [5] proposed the use of HTM, which was based on addition of 15 mg/l of hematin, 15 mg/l of NAD and 5 g/l of yeast extract to cationadjusted MHB. In 1990, the subcommittee of the NCCLS recommended the use of HTM as the reference method for H. influenzae antimicrobial susceptibility testing. Since the adoption of HTM as the reference method, a number of studies have reported on the failure of HTM to support the growth of all strains of H. influenzae as well as the influence of lot-to-lot MHB variability on overall test performance, reflecting the movement of clinical microbiology laboratories away from HTM [6] . Based on a survey among participating clinical microbiology laboratories, it is believed that HTM is used in 55% of laboratories (Ronald N. Jones, personal communication). Furthermore, the current practice in clinical microbiology laboratories in the United States is to focus only on b-lactamase-producing H. influenzae. In many laboratories, isolates from noninvasive specimens such as sputum are tested only for b-lactamase production; no antimicrobial susceptibility testing is performed.
Based on the above, and the need to address differing clinical microbiological and medical practice in Japan, the JSC-despite generally following CLSI recommendations in the past-made the decision to address the issue of poor growth on HTM by recommending replacing hemin with 2-5% lysed horse blood in the media formulation as the standard method for the antimicrobial susceptibility testing of H. influenzae [2] . With this as a backdrop, the JSC Subcommittee on Improving Microdilution Antimicrobial Agent Susceptibility Testing made the decision to compare the performances of the JSC and CLSI reference methods for H. influenzae susceptibility testing.
In phase I of the project, the committee focused on the lot-to-lot variation that is inherent to supplements of the medium for the antimicrobial susceptibility testing of H. influenzae, using the 2 QC strains recommended by the CLSI. We found that there was no lot-to-lot variation in the 3 lots when tested by both the CLSI and JSC methods.
The interlaboratory phase II study, which involved the use of 40 reference strains and consecutive isolates recovered at each participating site, revealed that b-lactam, AZM and CPFXMICs generated by the JSC method were higher, although in some cases differences were not statistically significant.
Barry et al. compared the performance of each method of microbroth dilution, agar dilution, E-test, and disk diffusion using 8 media including HTM for H. influenzae antimicrobial susceptibility testing. Compared to HTM, media supplemented with either lysed horsed blood with NAD supplementation, chocolate agar, or Fildes enrichment generated higher MICs or smaller zones of inhibition. The authors concluded that the inclusion of animal blood products led to better overall growth of H. influenzae [6, 7] .
With respect to the assessment of growth in phase II during the determination of MICs, visual readings from each site reported that superior growth was observed on JSC media compared to the CLSI HTM media; however, this difference did not reach statistical significance. During the interlaboratory phase, when 40 reference strains representing BLNAS, BLNAR, low BLNAR and BLPAR were used, OD readings after 24 and 48 h of incubation revealed that OD readings at 24 h were higher for the JSC medium than the CLSI medium. This difference in turbidity was even greater at 48 h (Tables 6, 7) . The failure to demonstrate a statistically significant difference in growth between the CLSI and JSC media based on visual assessment may be attributed to the fact that MIC readings are taken at 20-24 h of incubation, when turbidity differences are not as pronounced. If an OD reading of 0.2 is set as a cut-off for growth, many readings will fall below this threshold when using the CLSI medium, whereas less than one-half of all readings will fall below this threshold when using the JSC medium. It can thus be definitively concluded that superior growth is achieved with JSC medium. The one exception to better growth with JSC media was observed when testing T/S, in which case the CLSI HTM medium showed higher MIC values. Although not shown in Table 2 , the geometric mean MIC when ATCC 49766 H. influenzae was tested on the CLSI medium was 0.19/ 3.61 lg/ml, compared to 0.04/0.76 lg/ml with the JSC medium, which reflects a greater than twofold difference in dilution. Jorgensen et al. reported that MICs for T/S were lower when using 5% lysed horse blood compared to HTM [5] . The action of sulfonamides can be antagonized by peptones and other constituents. This antagonism can occur even in a non-peptone-containing medium such as MH medium. The neutralization of antagonism with respect to sulfonamides through the addition of lysed horse blood has been reported by the JSC Subcommittee on TrimethoprimSulfamethoxazole MIC Testing [8] .
The antimicrobial agents used in Japan and the United States to treat infections caused by H. influenzae differ. T/S is used more often in the United States, while it is rarely used in Japan. A lower MIC value for T/S is generated by the JSC method, but the subcommittee feels that this has minimal clinical implications, as categorical interpretations do not change. Among the ampicillin-resistant H. influenzae isolates recovered in Japan, BLNAR strains with lower MICs than b-lactamase-producing strains predominate. In contrast, BLPAR strains that generate high MICs are frequently isolated in the United States. If the JSC method is more effective at detecting BLNAR as it supports its growth better, this would be a positive contribution, as BLNAR strains are much more frequently seen in Japan than BLPAR strains. BLNAR strains exhibit an ampicillin MIC of about 4 lg/ml. Strains that are confirmed to be low-BLNAR strains based on molecular testing exhibit an MIC of B2 lg/ml, which is defined as intermediate resistance or susceptible according to the CLSI. Therefore, the use of the JSC method, which generates slightly higher MIC values than the CLSI method, should result in increased detection of BLNAR strains and reduce the rate of failure to detect these strains, which may be clinically significant.
This project reflects the third evaluation of the JSC method for testing the antimicrobial susceptibility of H. influenzae. In conclusion, this subcommittee concludes its activities on the comparison of CLSI and JSC methods with the annotations (Appendix) shown below. being 1.5-fold higher (range 1.15-1.86) for b-lactams and macrolides. This finding was previously reported by Jorgensen et al. [5] . Although the MICs for trimethoprimsulfamethoxazole generated by the JSC method tend to be higher than the CLSI, an analysis of the MICs by the JSC found that categorical interpretations did not change and would have minimal clinical implications. Furthermore, the poorer growth on CLSI method media led to higher false negative detection of BLNAR, which is more prevalent in Japan compared to the USA. Based on these findings, the JSC concludes that the JSC antimicrobial susceptibility MIC method for H. influenzae is superior to the CLSI method.
Note 2
With respect to trimethoprim-sulfamethoxazole, the JSC method generates MICs that are 1.5-fold lower as a result of lysed horse blood neutralizing peptones and other antagonists found in MH base media (TrimethoprimSulfamethoxazole MIC Testing Subcommittee [8] ). As trimethoprim-sulfamethoxazole is seldom used in Japan and categorical interpretations are not affected, the higher MICs generated using the JSC method have minimal clinical implications.
